PlainPharmaWatch

CMS Open Payments · Program Year 2024

Ipsen Biopharm Limited

Ipsen Biopharm Limited reported $13,054.05 across General Payments, Research, and Ownership to 5 physicians and teaching hospitals across 5 transactions.

See the rankings → How this is sourced
$13.1K
All-tracks total
5
Transactions
5
Recipients
#1601
of 1,925 companies

Ipsen Biopharm Limited reported $13,054.05 across all CMS Open Payments tracks (General + Research + Ownership) to 5 physicians and teaching hospitals in Program Year 2024 - ranking #1601 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $13,054.05, averaging $2.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer ipsen-biopharm-limited Ipsen Biopharm Limited

$13.1K · #1601/1,925 · 0.0% industry · PY2024

  • TOT $13.1K
  • RANK #1601
  • SHARE 0.0%
  • TXN 5
  • RCP 5
  • CAT 3
  • GEN $13.1K
  • TOP1 67.4%
  • PY 2024

Volume peers

Nearest volume peer: Atrium Medical Corporation ($13.1K)

Carmat$13.2KNotal Vision, Inc.$13.1KAtrium Medical Corporation$13.1KIpsen Biopharm Limited (this)$13.1KMedynus Inc$13.0K
All-tracks payment totals near Ipsen Biopharm Limited (CMS Open Payments PY2024)

Ipsen Biopharm Limited sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Ipsen Biopharm Limited

$13,054.05: that is what Ipsen Biopharm Limited reported in payments to 5 physicians and teaching hospitals during Program Year 2024, spread across 5 transactions ($2.6K per transaction, $2.6K per recipient). The company sits at rank #1601 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 3-category general-payment breakdown below at $13.0K (99.3% of General Payments, 3 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Consulting Fee" leads Ipsen Biopharm Limited's 3-category general-payment breakdown at $13.0K, 99.3% of the reported total.

How Ipsen Biopharm Limited divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$13.0K2. Travel and Lodging$83.553. Food and Beverage$10.50
Payment Type Amount Transactions
Consulting Fee $13.0K 3
Travel and Lodging $83.55 1
Food and Beverage $10.50 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $13,054.05 (100.0%) of $13,054.05 in this company's General Payments records across 2 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Ipsen Biopharm Limited

The five named recipients with the highest reported General Payments from this company

Alberto Esquenazi$8.8KRichard D Zorowitz$4.3K
  1. 1

    Alberto Esquenazi

    $8,794.05 across 4 reported transactions

  2. 2

    Richard D Zorowitz

    $4,260.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Ipsen Biopharm Limited's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ipsen Biopharm Limited.

Retropsoas Technologies, LLC

HHI 5606

FFF Enterprises, Inc.

HHI 5610

Inpeco North America, Inc

HHI 5612

BlueRock Therapeutics LP

HHI 5593

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Ipsen Biopharm Limited.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Ipsen Biopharm Limited's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.